Recent clinical guidelines suggest direct oral anticoagulants (DOACs) as treatment for cancer-associated thrombosis (CAT), but the strength of such recommendations was not clear. Newly released trials add uncertainties to the benefit and risk assessment between DOACs and conventional therapy (low-molecular-weight heparin [LMWH] or vitamin K antagonists [VKAs]).
Objective:
To evaluate the efficacy and safety of DOACs in patients with CAT, as compared with LMWH and VKAs.
Methods:
PubMed, EMBASE, Cochrane Library, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched. Randomized controlled trials (RCTs) that reported outcomes of DOACs for treating CAT were included. Relative risk (RR), risk difference, and 95% CIs were pooled using the Mantel-Haenszel method.
Results:
A total of 8 RCTs were included. DOACs significantly reduced VTE recurrence (RR = 0.59; 95% CI = 0.48-0.73) compared with conventional therapy. Results were similar in the LMWH and VKA subgroups. DOACs had a higher, though nonsignificant, risk of major bleeding compared with LMWH (RR = 1.33; 95% CI = 0.94-1.89) but lower risk of major bleeding compared with VKAs (RR = 0.60; 95% CI = 0.39-0.93). Findings were consistent across patients with active cancer and history of cancer.
Conclusion and Relevance:
DOACs have better efficacy to prevent recurrent VTE compared with conventional therapy. Regarding the safety profile, DOACs may carry higher risk of bleeding compared with LMWH but lower risk of bleeding compared with VKAs. Further studies are needed to inform the optimal anticoagulation approach for different types of cancers.
PrandoniPLensingAWAPiccioliA, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488. doi:10.1182/blood-2002-01-0108
4.
CheeCEAshraniAAMarksRS, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood. 2014;123:3972-3978. doi:10.1182/blood-2014-01-549733
5.
StreiffMBMilentijevicDMcCraeK, et al. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol. 2018;93:664-671. doi:10.1002/ajh.25059
6.
KearonCAklEAOrnelasJ, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-352. doi:10.1016/j.chest.2015.11.02
7.
FargeDBounameauxHBrennerB, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452-e466. doi:10.1016/S1470-2045(16)30369-2
8.
LymanGHBohlkeKFalangaA; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015;11:e442-e444. doi:10.1200/JOP.2015.004473
9.
CliveKElieAAJosephO, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-352. doi:10.1016/j.chest.2015.11.026
10.
RaskobGEvan EsNVerhammeP, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615-624. doi:10.1056/NEJMoa1711948
11.
YoungAMMarshallAThirlwallJ, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017-2023. doi:10.1200/JCO.2018.78.8034
12.
KhoranaAANobleSLeeAYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16:1891-1894. doi:10.1111/jth.14219
13.
StreiffMBHolmstromBAngeliniD, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Canc Netw. 2018;16:1289-1303. doi:10.6004/jnccn.2018.0084
14.
McBaneRDWysokinskiWELe-RademacherJG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18:411-421. doi:10.1111/jth.14662
15.
LiberatiAAltmanDGTetzlaffJ, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi:10.1136/bmj.b2700
16.
HigginsJPAltmanDGGotzschePC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928
17.
HigginsJPThompsonSG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558. doi:10.1002/sim.1186
18.
SchulmanSGoldhaberSZKearonC, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015;114:150-157. doi:10.1160/TH14-11-0977
19.
RaskobGEvan EsNSegersA, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016;3:e379-e387. doi:10.1016/S2352-3026(16)30057-6
20.
AgnelliGBullerHRCohenA, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13:2187-2191. doi:10.1111/jth.13153
21.
FrereCCrichiBLejeuneMSpanoJPJanusN. Are patients with active cancer and those with history of cancer carrying the same risks of recurrent VTE and bleeding while on anticoagulants?Cancers (Basel). 2020;12:917. doi:10.3390/cancers12040917
PrinsMHLensingAWABrightonTA, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1:e37-e46. doi:10.1016/S2352-3026(14)70018-3
24.
AgnelliGBecattiniCMeyerG, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599-1607. doi:10.1056/NEJMoa1915103
25.
SchulmanSKearonC. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694. doi:10.1111/j.1538-7836.2005.01204.x
KhoranaAAYannicelliDMcCraeKR, et al. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?Thromb Res. 2016;145:51-53. doi:10.1016/j.thromres.2016.07.013
28.
LiAGarciaDALymanGHCarrierM. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res. 2019;173:158-163. doi:10.1016/j.thromres.2018.02.144
29.
DongYWangYMaRL, et al. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis. J Thromb Thrombolysis. 2019;48:400-412. doi:10.1007/s11239-019-01871-4
30.
VedovatiMCGerminiFAgnelliGBecattiniC. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest. 2015;147:475-483. doi:10.1378/chest.14-0402
31.
SobierajDMBakerWLSmithE, et al. Anticoagulation for the treatment of cancer-associated thrombosis: a systematic review and network meta-analysis of randomized trials. Clin Appl Thromb Hemost. 2018;24:182-187. doi:10.1177/1076029618800792
32.
MulderFIvan EsNKraaijpoelN, et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thromb Res. 2019;185:13-19. doi:10.1016/j.thromres.2019.11.007
33.
KonstantinidesSVMeyerGBecattiniC, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019;54:1901647. doi:10.1183/13993003.01647-2019
34.
LeeAYY. Anticoagulant therapy for venous thromboembolism in cancer. N Engl J Med. 2020;382:1650-1652. doi:10.1056/NEJMe2004220
35.
EisenbergPRSiegelJEAbendscheinDRMiletichJP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest. 1993;91:1877-1883. doi:10.1172/JCI116404
36.
PerzbornEStrassburgerJWilmenA, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3:14-21. doi:10.1111/j.1538-7836.2005.01166.x
37.
GarciaDABaglinTPWeitzJISamamaMM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2, suppl):e24S-e43S. doi:10.1378/chest.11-2291
38.
MosarlaRCVaduganathanMQamarAMoslehiJPiazzaGGiuglianoRP. Anticoagulation strategies in patients with cancer: JACC review topic of the week. J Am Coll Cardiol. 2019;73:1336-1349. doi:10.1016/j.jacc.2019.01.017
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
